Immuron Limited saw a 34% increase in Q1 sales globally, with AUD$2.0 million in total revenue. Sales in Australia were up 52% to AUD$1.6 million, while sales in the USA increased by 44%. Sales in Canada, however, decreased by 92% due to the low travel season.

The growth in sales in Australia was attributed to increased marketing efforts, including social media campaigns and promotions. In the US, marketing initiatives such as an improved Amazon store and social media pages contributed to the increase in Q1 sales by 44%.

Q1 sales in Canada were impacted by the low travel season, but the company expects sales to pick up towards the end of the year with promotional activities and increased brand awareness efforts. Immuron Limited continues to focus on educating consumers and promoting Travelan® in Canada.

Travelan® is an immune supplement that targets pathogenic bacteria in the GI tract, reducing the risk of traveler’s diarrhea. It is available as a listed medicine in Australia, a natural health product in Canada, and a dietary supplement in the US. Immuron Limited is dedicated to developing and commercializing targeted polyclonal antibodies.

Read more at GlobeNewswire: Immuron Q1 FY26 YoY growth